Zobrazeno 1 - 10
of 88
pro vyhledávání: ''
Autor:
Dongsheng Tu, Timothy J. Price, Hagen F. Kennecke, Daniel L. Edelstein, Scott Kopetz, Frank Holtrup, Hannah Quinn, Anthony Dowers, Stanley R. Hamilton, Derek J. Jonker, John Zalcberg, Christos S Karapetis, Paul Waring, Jonathan M. Loree, Christopher J. O'Callaghan, Malcolm J. Moore
Publikováno v:
Clinical Cancer Research. 27:52-59
Purpose: Expanded RAS/BRAF mutations have not been assessed as predictive for single-agent cetuximab in metastatic colorectal cancer (mCRC), and low mutant allele frequency (MAF) mutations are of unclear significance. We aimed to establish cetuximab
Autor:
Peter S. Hammerman, Jing Yuan, Lesley A. Mathews Griner, Peter Aspesi, Daniel J. McKay, Gwynn Pardee, Hui Qin Wang, Kelli-Ann Monaco, Ribo Guo, Kenneth Crawford, Stephania Widger, Darrin Stuart, Vesselina G. Cooke, Karen Bui, Felipa A. Mapa, Yuji Mishina, Mariela Jaskelioff, Jeffrey A. Engelman, Paul Fordjour, Emma Labrot, Giordano Caponigro, Stacy Higgins, Jessi Ambrose, John Fuller, Jinsheng Liang, John Green, Scott Delach
Publikováno v:
Clinical Cancer Research. 27:2061-2073
Purpose: Targeting RAF for antitumor therapy in RAS-mutant tumors holds promise. Herein, we describe in detail novel properties of the type II RAF inhibitor, LXH254. Experimental Design: LXH254 was profiled in biochemical, in vitro, and in vivo assay
Autor:
Jan H. Beumer, Huichen Feng, Ashwin Reddy Sama, Thomas J. George, Corey Lipchik, Carmen J. Allegra, Melanie Finnigan, Philip J. Stella, James L. Wade, Katherine L. Pogue-Geile, Ying Wang, Patrick G. Gavin, Ashok Srinivasan, James J. Lee, Rim S. Kim, Norman Wolmark, Brian F. Kiesel, Peter C. Lucas, Fanny Piette, Samuel A. Jacobs, Ding Wang
Publikováno v:
Clinical Cancer Research. 27:1612-1622
Purpose: In metastatic colorectal cancer (mCRC), HER2 (ERBB2) gene amplification is implicated in anti-EGFR therapy resistance. We sought to determine the recommended phase II dose (RP2D) and efficacy of neratinib, a pan-ERBB kinase inhibitor, combin
Autor:
Ivette Valencia-Sama, Claire M. Robinson, Yoshihito Kano, Yagnesh Ladumor, Meredith S. Irwin, Teresa Adderley, Gabriella Christopher, Lynn Kee, Michael Ohh
Publikováno v:
Cancer Research. 80:3413-3423
Survival for high-risk neuroblastoma remains poor and treatment for relapsed disease rarely leads to long-term cures. Large sequencing studies of neuroblastoma tumors from diagnosis have not identified common targetable driver mutations other than th
Publikováno v:
Molecular Cancer Research. 18:835-846
Through the use of an unbiased, genome-scale CRISPR modifier screen, we identified NF1 suppression as a mechanism of resistance to EGFR inhibition in NRAS/KRAS/BRAFV600-wild-type colorectal cancer cells. Reduced NF1 expression permitted sustained sig
Autor:
Ulivi Paola, Laura Matteucci, Milena Urbini, Alessandro Passardi, Gianluca Tedaldi, Giorgia Marisi, Matteo Canale, Giovanni Martinelli, Giovanni Luca Frassineti, Chiara Molinari
Publikováno v:
Cancer Research. 81:541-541
The use of liquid biopsy in the clinical management of colorectal cancer (CRC) patients is not yet a routine clinical practice, although it could give important information for tumor baseline characterization and for monitoring during treatment. In t
Autor:
Tonghui Ma, Yanling Niu, Chengyun Geng, Sheng Yang, Xiaoyan Zhang, Xiaohui He, Kan Liu, Xin Zhang
Publikováno v:
Cancer Research. 81:1199-1199
Introduction: Although the contribution of mosaicism to tumorigenesis emerges during embryonic development, it is a very rare phenomenon in tumor patients. Only a few mosaic RAS mutations have been identified, such as NRAS G12D, NRAS G12S, KRAS G12D.
Publikováno v:
Cancer Research. 81:1103-1103
Background: Since the discovery of the oncogenic mutation B-Raf proto-oncogene, serine threonine kinase (BRAF) V600E, dabrafenib and trametinib (DT) combination therapies have been shown to have great anti-tumor activities against V600E-mutated non-s
Autor:
Reuben Kapur, Silvia Marino, Scott H. Boswell, D. Roodman, Larry D. Cripe, Santosh Kumar Pasupuleti, Lakshmi Reddy Palam, Hamid Sayar, Sravanti Rangaraju, Daniela N. Petrusca, Heiko Konig, Bhaskar Ramdas, Katie J. Sargent
Publikováno v:
Cancer Research. 80:800-800
FLT3 mutations (mFLT3) in acute myeloid leukemia (AML) carry a poor prognosis.The mandatory co-occurrence of other driver mutations with mFLT3 leads to suboptimal clinical responses with single agent FLT3 inhibitors (FLT3i). Pre-existing or emergent
Autor:
Emily Robb, Tatiana Hernandez-Guerrero, Jesús García-Foncillas, Michael M. Wick, Victor Moreno, Victoria Bonilla, Bernard Doger, Natalia Baños, Laura del Puerto, Cecilio Cadena
Publikováno v:
Cancer Research. 80:5061-5061
Background: Patient-derived xenografts (PDX) as xenotransplantation of human tumors into athymic nude mice have become the hallmark of preclinical modelling in cancer research. They are particularly useful in the characterization of targeted therapie